GW0742


GW0742 is a PPARδ/β agonist that has been investigated for drug use by GlaxoSmithKline.

Pharmacology

Pharmacodynamics

It is mixed PPAR-B agonist antagonist depending on its dosage. It has weak activity on multiple nuclear receptors as well. It is antagonistic at androgen receptors and VDR. In silico modelling suggest that it has effects on thyroid hormone receptors.

Chemistry

Derivatives

Multiple derivatives of GW0742 core structure have been developed. One of the compounds has the thiazole ring replaced with an oxazole ring inhibited VDR-meditated transcription with IC50 of 660 nM. Other novel analogues which are more potent than GWO742 with reduced toxicity have been developed as well.

Research

GW0742 has been shown to ameliorate experimentally induced pancreatitis in mice. Additionally, it prevents hypertension in diet induced obese mice, has been investigated as potential antidiabetic drug, and has anti-inflammatory effects.